


533,051

Rec'd PCT/PTO 26 APR 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/533051

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
WO 2004/037783 A2

(51) International Patent Classification<sup>7</sup>:

C07D

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2003/033440

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW); Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/420,582 22 October 2002 (22.10.2002) US(71) Applicant (*for all designated States except US*): DRUGABUSE SCIENCES S.A.S. [FR/FR]; 30 Boulevard Pasteur, F-75015 Paris (FR).**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): KUSMIEREK, Jacques [FR/FR]; 47 rue St. Lambert, F-75015 Paris (FR).

(74) Agents: RAE-VENTER, Barbara et al.; Rae-Venter Law Group, P.C., P.O. Box 1989, Monterey, CA 93942-1898 (US).

WO 2004/037783 A2

(54) Title: TREATMENT OF COGNITIVE IMPAIRMENT USING A SELECTIVE DOPAMINE D1 RECEPTOR AGONIST

(57) Abstract: Methods of using DAS-431 under conditions where it is administered at a dose that results in improved cognitive performance but without significant side effects are provided. Symptoms can be ameliorated during the period of treatment and, frequently, for substantially longer periods thereafter. In addition, the DAS-431 is provided at a level which does not negatively affect responsiveness to subsequent doses of DAS-431. Few adverse effects are observed, and the treatments can result in long term relief, so as to avoid frequent repetitive treatment.